Browsing Tag
Immunotherapy
45 posts
Kazia Therapeutics (NASDAQ: KZIA) unveils immune-boosting effects of paxalisib in advanced breast cancer at SABCS 2025
Find out how Kazia Therapeutics’ paxalisib is breaking new ground in breast cancer immunotherapy. Read the latest clinical insights from SABCS 2025.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
VRON-0200’s Spark and Fan model: Is Virion Therapeutics unlocking durable immunity against chronic hepatitis B?
Virion Therapeutics reports sustained immune responses up to one year after a single VRON-0200 dose for chronic HBV. Find out what makes this a potential game-changer.
Evaxion reports promising immune-biomarker results for AI-designed EVX-01 vaccine with KEYTRUDA
Discover how Evaxion’s AI-powered EVX-01 vaccine drives potent T-cell responses and strengthens its melanoma phase 2 program with KEYTRUDA.
Breakthrough allogeneic immunotherapy from Lunai Bioworks eliminates pancreatic tumors in preclinical study
Find out how Lunai Bioworks’ engineered dendritic-cell therapy achieved complete regression of pancreatic cancer in preclinical models and what it means for solid-tumor immunotherapy.
How Bio-Techne and Nucleai’s AI spatial biology breakthrough could redefine melanoma biomarker discovery
Discover how Bio-Techne and Nucleai’s AI-powered spatial biology workflow is advancing predictive biomarker discovery in melanoma and transforming immunotherapy research.
Breakthrough trial: Oncolytics Biotech’s pelareorep combo doubles response rate in advanced anal cancer
Find out how Oncolytics Biotech’s breakthrough trial doubled response rates in advanced anal cancer and set up a 2026 FDA path.
How Northwest Biotherapeutics’ acquisition of Advent BioServices may reshape its cell therapy strategy
Northwest Biotherapeutics acquires Advent BioServices to scale DCVax production and integrate UK manufacturing. Find out what this means for its immunotherapy pipeline.
Is Faron Pharmaceuticals (AIM: FARN) turning a corner? Bexmarilimab shows 85% ORR in HR-MDS as ESMO data boosts confidence
Faron Pharmaceuticals’ updated ESMO 2025 data shows 85% ORR and new biomarker insight for bexmarilimab in HR-MDS. Find out why this trial may redefine the biotech’s future.
Incyte’s dual-target antibody and KRAS G12D drug show early promise in hard-to-treat colorectal and pancreatic cancers
Find out how Incyte’s Phase 1 cancer data could transform treatment for colorectal and pancreatic patients—read what’s driving investor optimism today!